Aegle - Platform Technology
Advancement of extracellular vesicle therapy to the patient has been hampered by an inability to isolate extracellular vesicles in useful quantities while preserving their structural and functional integrity. EVs derived from MSCs enjoy the same immunosuppressant characteristics of their parent cells. However, when EVs are processed incorrectly, they can trigger an adverse inflammation response in vivo. The ability to properly isolate EVs from cells is critical to the success of extracellular vesicle therapy.
Traditional isolation processes can cause structural or functional damage to the EVs. Our preclinical research has shown that EVs isolated using traditional methods trigger an immune response in porcine wound models, resulting in adverse inflammation and lack of healing. In the same model, EVs isolated with our proprietary methodology accelerated healing, minimized/eliminated scarring and promoted blood vessel and nerve regeneration as well as hair follicle growth.
Aegle’s isolation process allows for the production of therapeutic-grade extracellular vesicles from bone marrow derived MSCs. Our proprietary extracellular vesicle isolation technology allows us to harness the healing power of mesenchymal stem cells without the risk of cell proliferation or engraftment, with higher production yields and at lower cost. Aegle’s EVs have the potential to address any indication where MSC therapy has shown promise.